Français Néerlandais Japonais Chinois Allemand Espagnol Portugais

AstraZeneca ramps up investment in Dunkerque

04 Nov 2013 | Investment, Health, Nutrition and food

AstraZeneca will invest €26 million in a new production line for the Symbicourt asthma inhaler at its Dunkerque plant. Existing lines will also be upgraded.

            Present in Dunkerque for over 20 years, pharmaceutical giant AstraZeneca has invested some €500 million in its local plant to date—outlays that reflect the facility’s strategic importance as the world’s sole producer of Symbicort inhalers. With demand for the asthma remedy on the rise, the plant needed new capacity. “The aerosol technology we use for this inhaler is fairly unique within our group, and is concentrated at Dunkerque,” says Plant Manager Dominique Bretaudeau.

            The plant, which exports 95% of its total output to the United States, has a long tradition of meeting challenges and adapting to changing patient needs. In addition to special projects, it invests around €2.5 million a year to upgrade and maintain equipment, enhance patient safety and improve packaging.

            AstraZeneca is one of the world’s top pharmaceutical companies and ranks fifth in the field in France. Its medicines cover six main therapeutic areas: cardiovascular & metabolic, infection, gastrointestinal, oncology, neurosciences and respiratory ailments. Sales total around $28 billion, with over $4 million invested in R&D each year.

 

Source: AstraZeneca / Press

Back to news

News

Coca Cola, a long-standing presence in Hauts-de-France

It is 30 years this year since Coca Cola moved to Socx, near Dunkirk. The development and investment which has taken place in those 30 years have made the plant one of the brand’s top three production sites in...

Cybersecurity: Vade Secure brought into the American fold

In Lille (Hauts-de-France), the cyber security start-up Vade Secure has raised 70 million euros from an American fund to accelerate its international expansion.

All news